Question 31

A company is currently marketing an implantable orthopedic medical device. The R&D department is
planning to change the material used for the implant. The R&D department states that the change does
not impact the safety and effectiveness of the product. What action should the regulatory affairs
professional take FIRST?
  • Question 32

    A company is developing a new medical device using innovative technology. Which of the following is
    MOST critical in working with regulatory authorities?
  • Question 33

    What is the BEST approach to ensure that raw materials, services, and sub-contractors at the level of the
    vendors comply with GMP requirements?
  • Question 34

    Which of the following is an example of an acceptable statement for an advertisement of an approved
    arthritis medication?
  • Question 35

    According to the GHTF, which of the following is NOT an exemption rule when evaluating the decision to
    report an adverse event?